NCT05277922

Effect of C21 on Forearm Blood Flow

A Phase 1, Open-label, Single-centre Study Investigating the Effect of C21 on Forearm Blood Flow in Healthy Male Subjects by Use of Strain-gauge Venous Occlusion Plethysmography

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Vicore Pharma AB · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the effect of C21 on forearm blood flow by use of strain-gauge venous occlusion plethysmography.

Detailed description

Subject will be screened for eligibility. Eligible subjects will receive ascending doses of C21 (3, 10, 30, 100, and 200 µg/min through local intra-arterial infusions for 5 min/dose. Forearm blood flow measurements will be performed in both arms during the last 2 minutes of each dose. Infusions of sodium nitroprusside will be performed as a positive control using the same methodology.

Conditions

• Study Vasodilatory Effects of C21

Interventions

Type	Name	Description
DRUG	C21	C21 in ascending doses of 15, 50, 150, 500 and 1000 µg
DRUG	Sodium Nitroprusside	Ascending doses of 4, 8 and 16 µg sodium nitroprusside Positive control

Timeline

• Start date: 2022-04-28
• Primary completion: 2022-05-11
• Completion: 2022-05-18
• First posted: 2022-03-14
• Last updated: 2025-04-23
• Results posted: 2025-04-23

Locations

1 site across 1 country: Sweden